UNRESECTABLE GASTRIC CARCINOMA
Clinical trials for UNRESECTABLE GASTRIC CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE GASTRIC CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE GASTRIC CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat HER2 cancers in early trial
Disease control Recruiting nowThis early-phase study tests a combination of two drugs (trastuzumab deruxtecan and azenosertib) in people with HER2-positive stomach, gastroesophageal junction, or other solid tumors that have spread or cannot be removed by surgery. The main goals are to find the safest dose and…
Matched conditions: UNRESECTABLE GASTRIC CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:51 UTC
-
New immune cocktail targets tough stomach cancers
Disease control Recruiting nowThis study tests a mix of immune cells (agenT-797) and three immunotherapy drugs (botensilimab, balstilimab, ramucirumab) plus chemotherapy (paclitaxel) for people with advanced stomach, esophageal, or gastro-esophageal junction cancer that has worsened after one prior treatment.…
Matched conditions: UNRESECTABLE GASTRIC CARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC